Search Results
Mar 31, 2026, 16:01 ET Co-Diagnostics Reports Full Year 2025 Financial Results
SALT LAKE CITY, March 31, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular
More news about: Co-Diagnostics
Mar 25, 2026, 08:00 ET Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Mar 20, 2026, 08:00 ET Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Mar 17, 2026, 09:00 ET Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Mar 16, 2026, 09:00 ET Co-Diagnostics to Present at Medical Korea 2026
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Mar 12, 2026, 09:00 ET Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Mar 10, 2026, 09:00 ET Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Feb 09, 2026, 09:00 ET Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai
Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Feb 05, 2026, 09:00 ET Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument
Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Feb 04, 2026, 09:00 ET Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform
Co-Diagnostics, Inc. (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Jan 12, 2026, 09:00 ET Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Dec 30, 2025, 09:00 ET Co-Diagnostics Announces Reverse Stock Split
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Dec 29, 2025, 09:00 ET Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Dec 18, 2025, 09:00 ET Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Dec 17, 2025, 09:00 ET Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
SALT LAKE CITY, Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Dec 09, 2025, 09:00 ET Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025
SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Dec 08, 2025, 12:36 ET Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular
More news about: Co-Diagnostics
Nov 20, 2025, 09:00 ET Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
SALT LAKE CITY, Nov. 20, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Nov 18, 2025, 09:00 ET Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA
SALT LAKE CITY, Nov. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Nov 13, 2025, 16:01 ET Co-Diagnostics Reports Third Quarter 2025 Financial Results
SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular
More news about: Co-Diagnostics
Nov 12, 2025, 09:00 ET Utah Governor Cox and BioUtah Recognize Co-Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia
Nov. 12, 2025 /PRNewswire/ -- Governor Spencer Cox joins Kelvyn Cullimore of BioUtah in recognizing Co-Diagnostics, Inc. (Nasdaq: CODX), a Utah diagnostics company with a patented platform for developing advanced molecular diagnostic tests, following its
More news about: Co-Diagnostics
Nov 05, 2025, 09:00 ET Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd
SALT LAKE CITY, Nov. 5, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a patented platform for developing advanced molecular diagnostic tests, today announced
More news about: Co-Diagnostics
Nov 03, 2025, 09:00 ET Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
SALT LAKE CITY, Nov. 3, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today
More news about: Co-Diagnostics
Oct 31, 2025, 09:00 ET Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast
SALT LAKE CITY, Oct. 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release
More news about: Co-Diagnostics
Oct 30, 2025, 13:57 ET Co-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia
SALT LAKE CITY, Oct. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced
More news about: Co-Diagnostics